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Dear Editor, 
Brugada Syndrome (BS) is a rare genetic condition affecting 
ionic channels of the heart, predisposing patients to poten-
tially fatal ventricular arrhythmias. It generally manifests 
during young adulthood, more frequently in males. Typical 
ECG pattern shows ST-segment elevation followed by a 
negative T wave in right pre-cordial leads, in the absence of 
structural heart disease. Three patterns can be recognized: 
1) coved; 2) saddleback and 3) coved or saddleback with 
ST < 1 mm. These can co-exist and ECG may be temporarily 
normal. Diagnosis is made in the presence of ECG pattern type 
1 and reinforced by clinical criteria like syncope, nocturnal 
agonal respiration, palpitations or dizziness, documented 
ventricular ﬁ brillation/tachycardia and family history of BS 
or sudden cardiac death (SCD). Provocative tests can be made 
with sodium channel blockers. Cardiac deﬁ brillator (ICD) 
implantation is recommended for all symptomatic patients 
and for those who, though asymptomatic, present inducible 
VT/VF during electrophysiologic study (EPS). Quinidine can 
be used safely as anti-arrhythmic agent when ICD implanta-
tion is not possible 1.
Case Report
A 67-yr-old male was diagnosed with colon cancer and 
scheduled for a sub-total colectomy. Six years before, he 
had an ICD (VVIR) implanted after asymptomatic type I 
Brugada syndrome was diagnosed based on typical ECG 
pattern, easily inducible VT on EPS. Before surgery, ICD 
was externally disabled to prevent inadequate activation 
by monopolar cautery; from then on an external deﬁ brilla-
tor being permanently available. After premedication with 
midazolam (1mg), an epidural thoracic catheter was placed. 
Induction was achieved with fentanyl (0.02 mg.kg-1) and 
propofol (2 mg.kg-1). Orotracheal intubation was performed 
uneventfully after neuromuscular blockade with rocuronium 
(0.6 mg.kg-1). Anesthesia was maintained with sevoﬂ urane, 
rocuronium and epidural fentanyl. Monitorization included 
5-lead ECG and ST trend analysis, invasive arterial blood 
pressure, peripheral arterial oxygen saturation, end tidal 
CO2, esophageal temperature, BIS, neuromuscular blockade 
and urine output. No dysrhythmia or ST-segment elevations 
were noted during the entire procedure, which lasted ap-
proximately 2 hours. Neuromuscular blockade was reversed 
with sugammadex (2 mg.kg-1) and the patient extubated 
without incidents. Analgesia was provided with epidural 
ropivacaine and morphine. In the post anesthetic care unit, 
ICD was re-activated. After 6 days the patient was discharged 
home, with no adverse events being reported.
Discussion
In BS patients, several pharmacological and physiological 
factors can initiate malignant arrhythmias, including medi-
cations routinely used in anaesthetic practice, electrolyte 
disturbances, temperature variations, physiologic stress and 
increased vagal activity, all  of which must be kept in the 
mind of the anesthetist managing these patients 2,3.
On this subject, recommendations are sparse and lim-
ited by conﬂ icting results found in literature, probably due 
to inter individual variability, medication associations and 
doses and physiologic circumstances 4. Propofol has been as-
sociated with the development of ventricular arrhythmias in 
prolonged infusions, suggesting a possible similar mechanism 
to that responsible for arrhythmogenesis in propofol infusion 
syndrome, rather than with bolus dosing for induction 5. Local 
anesthetics - such as class Ib anti-arrhythmic agents and block 
sodium channels - should raise concern to the anesthesiolo-
gist. Though, when used cautiously, with the dose minimized 
and close monitoring of the patient, regional techniques 
may be helpful in avoiding light anesthesia and analgesia, 
factors known to affect autonomic tone. Particular atten-
tion should be paid to bupivacaine which stays bound to the 
sodium channels for longer periods of time and causes greater 
depression of rapid phase depolarization in the ventricular 
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muscle. Regarding volatile anesthetics, preference is given 
to sevoﬂ urane as it provides a better stability of QT interval. 
Though it has been safely used 6, neostigmine is best avoided 
in the reversal of neuromuscular blockade as it may augment 
ST segment elevation 7. 
In this case we preferred to use sugammadex, a 
γ-cyclodextrine with a lipophylic center that encapsulates 
rocuronium (and vecuronium) molecules forming water solu-
ble complexes that then are excreted in urine. Thereby, rapid 
and effective reversal of neuromuscular blockade is achieved, 
decreasing the risk of residual paralysis, particularly relevant 
in the case of major abdominal surgery, avoiding the side 
effects associated with neostigmine and anti-muscarinic 
agents, notably signiﬁ cant in BS patients.
Conclusions
BS is a rare though potentially fatal condition. Threatening 
arrhythmias can be triggered by several factors often present 
during surgical procedures, putting patient safety at stake. 
Most importantly, in the anesthetic management of BS pa-
tients, the decision of using each drug must be made after 
extensive consideration and in controlled conditions, avoiding 
other factors that are known to have the potential to induce 
arrhythmias like electrolyte and temperature disturbances, 
maintaining a close monitoring on hemodynamic status of the 
patient and being prepared to readily interfere if such events 
occur. Regarding the reversal of neuromuscular blockade, 
suggamadex presents as a safer option in BS patients, granting 
the desired goal while avoiding undesirable cardiovascular 
and autonomic effects.
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Figure 1  Patient ECG, Showing Type II (saddleback) Pattern in V2.
